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miRNAs have been identified to play a crucial role in carcinogenesis through their binding to various regulatory proteins. 
One such causative molecule identified as miRNA155, which when overexpressed is responsible for carcinogenesis and also 
leads to telomere fragility. miRNA155 levels in the blood are used for early screening of cancer. Several anticancer drugs such 
as doxorubicin have been identified, which act by binding to DNA and DNA binding enzymes to check their expression levels. 
In this study doxorubicin and its similar compounds were used to analyze their binding with miR155 DNA for inhibition of 
miRNA155 synthesis and their binding energies were calculated. Based on the docking, ADME, and toxicity results 
Morpholinyl Doxorubicin was used for molecular dynamics studies and was identified as a potential drug candidate. 
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miRNAs are 18–24 nucleotides in length1,2 and play 
crucial roles in biological phenomena including cellular 
proliferation, development, apoptosis, tumorigenesis, 
and stress response. Abnormal miRNA expression has 
been analyzed in numerous solid tumors, such as breast 
cancer3,4, due to their dysregulated expression in cancer 
cells and are stable in blood5-7. In breast cancer, several 
studies have supported an abnormal expression of 
miRNA-155 (MIR-155) in patients with the disease8. 
The overexpression of MIR-155 has been identified as 
a breast cancer risk factor9, which is associated with 
different clinical and pathological markers, tumour 
subtype, metastasis events, and invasive properties of 
breast cancer, poor survival rates, alongside high 
tumour grade, advanced stage, and lymph node 
metastasis8. miR155 is involved in controlling several 
mechanisms of cell survival, cell growth, radio/chemo-
resistance8,10,11, inhibiting different target genes 
including FOXO3A, VHL, and SOCS1. 
Various treatment plans for cancer patients are 
available, depending upon the type and the stage 
identified during diagnosis12. One such drug, that has 
been identified to be effective against cancer is 
doxorubicin13,14. Doxorubicin has exhibited great 
potential for the treatment of breast cancer and is 
considered as one of the most effective Food and Drug 
Administration-approved chemotherapeutic drugs15. 
The mode of action of doxorubicin includes its binding 
to DNA associated enzymes and also intercalation 
between base pairs of the DNA double helix16,17, which 
results in a variety of cytotoxic effects that happen in 
concurrence with anti-proliferation, resulting in DNA 
damage17,18. Other doxorubicin actions include free 
radical generation which causes further DNA damage, 
inhibition of macromolecule production, DNA 
unwinding/separation, and increase in alkylation19,20.  
In recent times for designing rational drugs, the  
in silico methods have gained attention, because of 
their efficiency, cost- effectiveness, and time- saving 
capabilities. The drug design process involves 
screening of potential drug- like lead compounds 
through molecular docking and then the ADMET 
(absorption, distribution, metabolism, excretion, and 
toxicity) analysis of the screened molecules21. These 
models have inexpensive and high-throughput 
optimization ability for parallel analysis of 
bioavailability and activity along with the safety in the 
process of rationalized drug development. Because of 
the costly ADMET experimental procedures, in silico 
method for ADMET analysis in early drug discovery 
has become a way of choice22. 
In this study the molecular binding of miR155 DNA 
with doxorubicin and its similar compounds is analyzed 
for their binding affinity and as these compounds can 
bind to and inhibit the expression of DNA. ADMET 
analysis of all the selected drugs has been done for 
predicting suitable drugs for cancer treatment. 
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Materials and Methods 
DNA Sequence 
The gene sequence of miR155 for Homo sapiens 
was retrieved from gene bank database with accession 
number NR_030784.1 in the FASTA format from the 
NCBI website (https://www.ncbi.nlm.nih.gov/)23. The 
retrieved sequence is CTGTTAATGCTAATCGTGA 
TAGGGGTTTTTGCCTCCAACTGACTCCTACA
TATTAGCATTAACAG.  
 
DNA structure 
The pdb structure file for the retrieved sequence was 
generated into B type helix using the online tool make-
na server available at http://casegroup.rutgers.edu/ 
casegr-sh-2.2.html24. After conversion, the pdb file for 
the given DNA sequence was downloaded and saved. 
 
Ligands 
Doxorubicin is reported to bind to DNA, hence it 
was selected for the studies, and similarity search was 
done on Pubchem and molecules showing more than 
95% similarity were selected for the study. The  
3 dimensional (3D) structure files for Doxorubicin 
and its similar compounds were downloaded from 
PubChem database (https://pubchem.ncbi.nlm.nih. 
gov/)25. Thenames and structures of the retrieved 
compounds are represented in (Table 1). After saving 
the structure files these were converted into pdb 
format necessary for analyzing molecular binding 
studies using the tool Open Babel26. 
 
Docking 
Molecular docking of selected ligands with miR155 DNA 
Molecular binding studies were performed using 
AutoDock Tools 1.5.627. The process included initial 
processing of DNA and ligand files and saving them 
into pdbqt format. In the next step, the grid was setup 
onto the DNA molecule and grid parameter file was 
saved. Then after running AutoGrid, the docking was 
performed and the results were analyzed using 
AutoDock Tools for estimation of binding energies, 
hydrogen bonds formed, and bond length of formed 
hydrogen bonds. 
 
ADME and Toxicity analysis 
The ADME analysis of the selected compound was 
performed using the online tool ALOGPS 2.1 
available at http://www.vcclab.org/lab/alogps/28. This 
Table 1 — Docking results of selected ligands with miR155 DNA 
S. No. Ligand Chain Base Bond Length (A) Binding Energy (kcal/mol) 
1 Doxorubicin B A39 2.199 10.94 
2 Doxorubicin-N-4-hydroxyphenoxyacetamide B G33 2.03 6.21 
3 Nemorubicin B 
G30 1.989 
9.14 G33 2.167 
4 YM4 Doxorubicin Analog B A32 1.965 9.03 
5 Epirubicin B A40 2.201 10.41 
6 Mra-CN 
A G31 1.693 
7.64 B G33 2.199 
B G34 2.031 
7 Cyanomorpholinoadriamycin B G30 2.167 8.77 
8 YM1 Doxorubicin Analog B 
G34 1.934 
10.54 G34 2.087 
9 Morpholinyl Doxorubicin B A36 2.098 9.33 
10 Adriamycin B A38 1.913 9.44 
11 Oxazolocyanomorpholino Adriamycin 
A G31 2.199 
10.7 B G34 1.773 
12 Lys(6)-LHRH-doxorubicin B 
G31 2.081 
3.21 G33 1.919 
13 Adriamycinone B G33 2.164 7.18 
14 Pirarubicin B A36 1.988 9.57 
15 Cyanomethyladriamycin B A39 2.003 9.47 
16 NSC169534 B 
G30 2.114 
10.79 G31 1.822 
A32 2.08 
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tool was used to calculate the logP and logS values of 
the compounds, conferring to their absorption and 
distribution in the body, respectively. The selected 
compounds were further subjected to toxicity 
prediction for the parameters including subcellular 
localization, category of acute oral toxicity, effects on 
blood- brain barrier, carcinogenicity, and LD50 
values using the online tool admetSAR available at 
http://lmmd.ecust.edu.cn/admetsar1/home/29.  
 
Molecular dynamics Analysis 
The final identified compound was then analyzed 
for molecular dynamics simulation analysis using 
NAMD30. For this purpose, the molecule-DNA 
complex was saved as pdb file and then NAMD tool 
was used for molecular dynamics analysis with a 
binding time of 10ns. The plots for potential energy 
and RMSD (root mean square deviation) were plotted. 
 
Results and Discussion 
miR155 DNA  
The retrieved FASTA sequence for the miR155 
gene was converted into a double helix structure with 
B type helix and saved as pdb structure file as 
represented in supplementary (Fig. 1). 
 
Docking 
Binding of miR155 DNA with selected ligands 
The molecular binding studies of the DNA with 
Doxorubicin and its similar compounds were 
performed using AutoDock Tools 1.5.6. The docking 
programme has been employed frequently as a very 
quick and reliable method for screening of the 
phytochemicals potency against various disorders. 
Autodock executes this task by identifying the most 
similar component having a strong binding affinity 
towards the specific target with the lowest binding 
energy and predicts the binding orientation and 
conformation31.The results of the molecular docking 
studies along with binding energies, hydrogen bond 
formation, and bond length of the formed hydrogen 
bond are represented in (Table 1). 
From the (Table 1) it is evident that the ligands 5, 
8, 11 and 16 having energy values of 10.41, 10.54, 
10.7 and 10.79 kcal/mol, respectively, show the 
binding energies comparable to the binding energy of 
doxorubicin having an energy value of 10.94 
kcal/mol, thus exhibiting the capability to bind to and 
damage miR155 DNA to inhibit its expression. 
The docking images of different ligands with 
miR155 DNA are represented in (Fig. 2A & B), where 
the formed hydrogen bonds are represented by dark 
 
 
Fig. 2A & B — Docking poses of the selected ligands with miR155 DNA 
 
Fig. 1 — Generated 3-dimensional structure of miR155 DNA 
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green lines. The bond length of the formed hydrogen 
bonds was measured. Ligand 5 formed hydrogen bond 
with the 40th adenine of chain B, with the hydrogen 
bond length being 2.201 A. Similarly, ligand 8 formed 
two hydrogen bonds with G34 of chain B having bond 
lengths of 1.934 and 2.087 A, respectively. Ligand 11 
exhibited binding with G31 and G34 of chains A and B 
of miR155 DNA with hydrogen bond lengths of 2.199 
and 1.773 A, respectively. Whereas, ligand 16 
exhibited binding with G30, G31, and A32 of chain B 
of miR155 DNA having hydrogen bond lengths of 
2.114, 1.822, and 2.08 A, respectively. All other 
ligands have higher binding energies thus showing 
comparatively lower binding affinities with miR155 
DNA. Out of these ligands, 11 is showing binding with 
both the chains/helices of miR155 DNA and also 
having binding energy compared to the binding energy 
of doxorubicin which indicates its intercalation 
between two strands of the DNA and thus can act as a 
more effective candidate for inhibiting the expression 
of oncogenic miR155 RNA.  
 
ADME and Toxicity analysis 
The ADME analysis was carried out to further 
screen the selected molecules for and their logP and 
logS values, representing the lipophilicity and drug 
solubility in water. 
The lipophilicity of the potential drug candidates is 
calculated in terms of logP, which represents the 
partition of the drug in water and octane at 
equilibrium. This parameter signifies the absorption 
of the drug into the cells. The safe range of logP 
values is regarded as 0-532. It is evident from  
(Table 2) that except Adriamycin, all other ligands 
exhibit positive logP values falling in the safe limit 
(logP < 5). The aqueous solubility of a compound 
impacts the distribution of the drug thus leading to 
lower distribution of the drug with a decrease in 
solubility and also most of the marketed drugs have 
logS value higher than 433. All the selected ligands 
exhibited logS values in an acceptable range. 
The toxicity evaluations of potential drug candidates 
are necessary to analyze their harmful and deleterious 
effects on the human body. The selected molecules 
were analyzed for their carcinogenicity, subcellular 
localization, acute oral toxicity, blood- brain barrier 
penetration capability, and LD50 values (Table 2)29.  
During the analysis it was observed that all the 
selected ligands are negative for their carcinogenicity 
and blood- brain barrier penetration, hence the further 
screening can be done Based on their subcellular 
localization and LD50 values. Also, all the ligands 
exhibited category III of acute oral toxicity, thus 
Table 2 —ADME and Toxicity analysis of selected drug candidates 
S. No. Compound 
ADME  Toxicity 
logP logS Subcellular localization Carcinogenicity 
Acute Oral 
Toxicity BBB LD50 
1 Doxorubicin 1.41 2.67 Nucleus No III - 2.664 
2 Doxorubicin-N-4-hydroxyphenoxyacetamide 2.21 3.66 Nucleus No III - 2.676 
3 Nemorubicin 1.73 2.78 Nucleus No III - 3.1607 
4 YM4 Doxorubicin Analog 0.46 3.3 Nucleus No III - 2.5729 
5 Epirubicin 1.41 2.67 Nucleus No III - 2.6644 
6 Mra-CN 1.95 2.59 Nucleus No III - 2.7405 
7 Cyanomorpholinoadriamycin 1.95 2.59 Nucleus No III - 2.7405 
8 YM1 Doxorubicin Analog 1.36 3.34 Nucleus No III - 2.5729 
9 Morpholinyl Doxorubicin 1.79 2.75 Nucleus No III - 2.922 
10 Adriamycin -0.08 3.17 Nucleus No III - 2.7374 
11 Oxazolocyanomorpholino Adriamycin 2.1 2.38 Lysosome No III - 2.7359 
12 Lys(6)-LHRH-doxorubicin 0.95 4.43 Lysosome No III - 2.7206 
13 Adriamycinone 1.09 2.55 Mitochondria No III  2.4516 
14 Pirarubicin 2.06 3.32 Nucleus No III - 2.6624 
15 Cyanomethyladriamycin 1.36 2.92 Nucleus No III - 2.7125 
16 NSC169534 1.41 2.67 Nucleus No III - 2.6644 
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signifying that their LD50 values lie in the range of 
500 mg/kg to 5000 mg/kg body weight. Out of all the 
screened compounds, the ones showing subcellular 
localization in the nucleus and the compounds with 
the highest LD50 values can be forwarded for further 
studies. 
 
Molecular Dynamics Simulation 
Based on the results of autodock, ADME and 
toxicity analysis, Morpholinyl Doxorubicin was 
selected for molecular dynamics analysis by using 
NAMD for 10 nanoseconds (10ps time step, 1000 
steps) as a potential candidate that can bind to  
miR-155 DNA and inhibit its expression. The plots 
for potential energy and RMSD were plotted (Figs. 3 
& 4). The potential energy plot suggests the 
stabilization of the complex formed and the results 
were further validated by RMSD values (being in the 
order of 1*10-2)30. Thus showing the effective binding 
of the ligand/ drug candidate with the DNA molecule.  
 
Conclusion 
The methods of cancer treatments have gained 
much attention presently due to the low efficacy of 
the drugs, higher levels of toxicity and side effects. In 
this light, there is a need to identify new drugs that 
have the capability to inhibit oncogenes and other 
carcinogenic agents, thus inhibiting the process of 
carcinogenesis. In this study, the doxorubicin and its 
similar compounds were studied for inhibition of 
oncogenic miR155, over expression of which can lead 
to breast and other types of cancer. The compound 
Morpholinyl Doxorubicin was identified as a potential 
drug candidate based on ADMET and molecular 
dynamics analysis. The efficacy and effectiveness of 
these compounds further need to be validated in a wet 
lab along with their toxicity evaluations both in vitro 
and in vivo before preparation of their dosage forms. 
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